Collaborating To Get Biopharma In The Fast Lane

By Stephanie Sutton

This article originally appeared in: the Medicine Maker;  September 2017

Having been in the industry for more than 25 years, Patrick Guertin knows that cells can be temperamental and don’t like to be rushed, but in today’s biopharma industry speed to market is key. Guertin is a Global Technical Manager for Cytiva, where he focuses on upstream development and supporting the company’s Fast Trak services for process development and manufacturing.

Cytiva is working with a number of biopharma companies to help them advance their bioprocesses, including Roivant Sciences. Roivant specializes in picking up abandoned drugs from other companies that still have great potential, and has recently collaborated with Cytiva on an investigational orphan drug product – RVT-801. We speak with Guertin and Alex Tracy, Vice President of Pharmaceutical Development at Roivant, to learn more about the challenges of speed to market and the details of their collaboration.